{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:33Z","timestamp":1759335273538,"version":"3.40.5"},"reference-count":26,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,9,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Panitumumab is an EGFR inhibitor used for the treatment of metastatic\ncolorectal cancer (mCRC), even if its use is related to skin toxicity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p> We report the development of forearm panniculitis in two women during the\ntreatment with Panitumumab (6 mg\/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5-\nfluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In both patients, clinical, laboratory and radiological evaluation documented the presence\nof a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation\nand antimicrobial + corticosteroid treatment induced a remission of skin manifestations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Conclusion:<\/jats:title>\n<jats:p>We reported for the first time the development of panniculitis during Panitumumab\ntreatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or\noxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with\nmCRC, without the development of adverse drug reactions or drug-drug interactions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886314666190522094713","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T15:28:41Z","timestamp":1568734121000},"page":"233-237","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-7070","authenticated-orcid":true,"given":"Ciliberto","family":"Domenico","sequence":"first","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8508-1636","authenticated-orcid":true,"given":"Ierardi","family":"Antonella","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroleo","family":"Benedetto","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0086-9913","authenticated-orcid":true,"given":"Scalise","family":"Luigi","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5223-4402","authenticated-orcid":true,"given":"Cimellaro","family":"Antonio","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3440-2916","authenticated-orcid":true,"given":"Colangelo","family":"Lidia","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Oncology and Elderly Operative Units, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-5109","authenticated-orcid":true,"given":"Spaziano","family":"Giuseppe","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University Vanvitelli of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":true,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Clinical Pharmacology and Pharmacovigilance Unit, MaterDomini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/j.1468-3083.2012.04466.x","volume":"27","author":"Ra H.S.","year":"2013","unstructured":"Ra H.S.; Shin S.J.; Kim J.H.; Lim H.; Cho B.C.; Roh M.R.; The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 2013,27(1),e53-e59","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","volume":"14","author":"Rosen A.C.","year":"2013","unstructured":"Rosen A.C.; Case E.C.; Dusza S.W.; Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 2013,14(4),327-333","journal-title":"Am J Clin Dermatol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/1471-2407-12-438","volume":"12","author":"Thaler J.","year":"2012","unstructured":"Thaler J.; Karthaus M.; Mineur L.; Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer 2012,12,438","journal-title":"BMC Cancer"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"Douillard J.Y.","year":"2013","unstructured":"Douillard J.Y.; Oliner K.S.; Siena S.; Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013,369(11),1023-1034","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg L.S.","year":"2014","unstructured":"Schwartzberg L.S.; Rivera F.; Karthaus M.; PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014,32(21),2240-2247","journal-title":"J Clin Oncol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","volume":"4","author":"Li T.","year":"2009","unstructured":"Li T.; Perez-Soler R.; Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009,4(2),107-119","journal-title":"Target Oncol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1345\/aph.1M241","volume":"43","author":"Tan E.H.","year":"2009","unstructured":"Tan E.H.; Chan A.; Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009,43(10),1658-1666","journal-title":"Ann Pharmacother"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"Perez-Soler R.","year":"2004","unstructured":"Perez-Soler R.; Chachoua A.; Hammond L.A.; Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004,22,3238-3247","journal-title":"J Clin Oncol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo C.A.; Busto U.; Sellers E.M.; A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981,30(2),239-245","journal-title":"Clin Pharmacol Ther"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2050-6511-15-3","volume":"15","author":"Mumoli L.","year":"2014","unstructured":"Mumoli L.; Gambardella A.; Labate A.; Rosacea-like facial rash related to metformin administration in a young woman. BMC Pharmacol Toxicol 2014,15,3","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00592-014-0707-7","volume":"52","author":"Succurro E.","year":"2015","unstructured":"Succurro E.; Ruffo M.; De Sarro G.; Gallelli L.; Arturi F.; Bilateral lower limbs edema with \u201cwooden\u201d character induced by insulin glargine treatment. Acta Diabetol 2015,52(4),809-811","journal-title":"Acta Diabetol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1600-0560.2007.00947.x","volume":"35","author":"Misago N.","year":"2008","unstructured":"Misago N.; Inoue T.; Narisawa Y.; Delayed reaction after an octopus bite showing a giant cell-rich granulomatous dermatitis\/panniculitis. J Cutan Pathol 2008,35(11),1068-1072","journal-title":"J Cutan Pathol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1574886311666160405110515","volume":"13","author":"Vasapollo P.","year":"2018","unstructured":"Vasapollo P.; Cione E.; Luciani F.; Gallelli L.; Generalized intense pruritus during Canagliflozin treatment: Is it an adverse drug reaction? Curr Drug Saf 2018,13(1),38-40","journal-title":"Curr Drug Saf"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1345\/aph.1E326","volume":"38","author":"Gallelli L.","year":"2004","unstructured":"Gallelli L.; Ferraro M.; Mauro G.F.; De Sarro G.; Generalized exfoliative dermatitis induced by interferon alfa. Ann Pharmacother 2004,38(12),2173-2174","journal-title":"Ann Pharmacother"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2014.06.011","volume":"71","author":"Bergman H.","year":"2014","unstructured":"Bergman H.; Walton T.; Del Bel R.; Managing skin toxicities related to panitumumab. J Am Acad Dermatol 2014,71(4),754-759","journal-title":"J Am Acad Dermatol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"e1004969","DOI":"10.1080\/23723556.2015.1004969","volume":"2","author":"Holcmann M.","year":"2015","unstructured":"Holcmann M.; Sibilia M.; Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2015,2(4),e1004969","journal-title":"Mol Cell Oncol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000317132","volume":"33","author":"Reck M.","year":"2010","unstructured":"Reck M.; Gutzmer R.; Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 2010,33(8-9),470-479","journal-title":"Onkologie"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.intimp.2019.01.023","volume":"69","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Jiang X.; Gu Y.; Chen Y.; Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor. Int Immunopharmacol 2019,69,79-87","journal-title":"Int Immunopharmacol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1043-6618(03)00003-3","volume":"47","author":"Gallelli L.","year":"2003","unstructured":"Gallelli L.; Ferreri G.; Colosimo M.; Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. Pharm Res 2003,47,493-499","journal-title":"Pharm Res"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1574886312666170616090640","volume":"12","author":"Gallelli L.","year":"2017","unstructured":"Gallelli L.; Siniscalchi A.; Palleria C.; Adverse Drug Reactions Related to drug administration in hospitalized patients. Curr Drug Saf 2017,12(3),171-177","journal-title":"Curr Drug Saf"},{"key":"ref=21","author":"Caroleo B","year":"2015","unstructured":"Caroleo B; Staltari O; Gallelli L; Perticone F; Reactivation of\n\tchronic hepatitis B during treatment with tenofovir disoproxil\n\tfumarate: Drug interactions or low adherence?  BMJ Case Reports 2015; 2015","journal-title":"BMJ Case Reports 2015;"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/157488609789006912","volume":"4","author":"Gallelli L.","year":"2009","unstructured":"Gallelli L.; Staltari O.; Palleria C.; De Sarro G.; Ferraro M.; Hepatotoxicity induced by methimazole in a previously health patient. Curr Drug Saf 2009,4,204-206","journal-title":"Curr Drug Saf"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"Lacouture M.E.","year":"2011","unstructured":"Lacouture M.E.; Anadkat M.J.; Bensadoun R.J.; Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011,19(8),1079-1095","journal-title":"Support Care Cancer"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-4632.2010.04791.x","volume":"50","author":"Balagula Y.","year":"2011","unstructured":"Balagula Y.; Garbe C.; Myskowski P.L.; Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011,50(2),129-146","journal-title":"Int J Dermatol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","volume":"10","author":"Perez-Soler R.","year":"2005","unstructured":"Perez-Soler R.; Delord J.P.; Halpern A.; HER1\/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum. Oncologist 2005,10,345-356","journal-title":"Oncologist"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00280-015-2916-3","volume":"77","author":"Arbitrio M.","year":"2016","unstructured":"Arbitrio M.; Di Martino M.T.; Barbieri V.; Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis. Cancer Chemother Pharmacol 2016,77,205-209","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T12:12:06Z","timestamp":1571400726000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172235\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666190522094713","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}